ReviewInternational journal of cancer2026
Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group.
Review in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group.International journal of cancer · 2026Review
- Axillary surgical de-escalation after neoadjuvant therapy in breast cancer: current evidence, clinical controversies, and future directions.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence on the concurrent administration of human epidermal growth factor receptor 2-targeted agents (trastuzumab, pertuzumab, trastuzumab emtansine, trastuzumab deruxtecan), cyclin-dependent kinase 4 and 6 inhibitors (palbociclib, ribociclib), immunotherapies (pembrolizumab), poly(ADP-ribose) polymerase inhibitors (olaparib), and new antibody-drug conjugates (sacituzumab govitecan). Drawing from extensive clinical experience, including retrospective and prospective studies conducted at Institut Curie, this review provides a comprehensive analysis of the feasibility and safety of these novel combinations, ensuring an evidence-based approach to optimizing breast cancer treatment strategies. In addition to systemic therapy considerations, this review highlights the importance of advanced RT techniques, including proton therapy, isocentric lateral decubitus positioning, and volumetric modulated arc therapy with deep inspiration breath hold, which play a crucial role in minimizing cardiac and pulmonary toxicities, particularly in patients receiving cardiotoxic agents or those with predisposing risk factors. By integrating both systemic advancements and optimized radiation delivery, this review provides a practical framework for the safe and effective combination of modern breast cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.